Pharmaceuticals licensed its ssRNAi
technology to Alnylam
Pharmaceuticals for up to $31 million as part of a new collaborative effort. Alnylam gets access to Isis' intellectual property and expertise concerning ssRNAi antisense
drugs, and both companies will be allowed to develop drugs with the new technology.
In addition to the new collaboration, Isis and Alnylam also agreed to extend their broad cross-licensing arrangement regarding double-stranded RNAi that was established in 2004.
Under the terms of the ssRNAi agreement, Alnylam will pay Isis $11 million upon signing the deal, followed by milestone payments: $10 million when in vivo efficacy in rodents is demonstrated (or 18 months), $5 million after in vivo efficacy in nonhuman primates, and $5 million at the start of the first clinical trial with an ssRNAi drug. In addition, Alnylam will fund at least $3 million in research activities per year for three years.
Also, initially Isis is eligible to receive up to 50% of any sublicense payments due to Alnylam based on Alnylam partnering of ssRNAi products. This will decline over time as Alnylam’s investment in the technology and drugs increases. In turn, Alnylam is eligible to receive up to 5% of any sublicense payments due to Isis based on Isis’ partnering of ssRNAi products. Each firm will receive royalties on any ssRNAi products developed by the other company.
Alnylam and MIT Advance Research on Systemic Delivery of RNAi Therapeutics Using Lipidoid Formulations (Mar. 5, 2009)
Alnylam Obtains $20M Up Front in Deal with Cubist Covering RSV Pipeline (Jan. 9, 2009)
Isis Obtains $1.5M to Improve Properties of RNAi-Based Drugs (Oct. 3, 2007)
Regulus Therapeutics Spun Out of Isis and Alnylam to Focus on miRNA Drugs (Sept. 7, 2007)
Isis and Alnylam Afforded Patent Claiming Modifications of Oligonucleotide Therapeutics (Nov. 27, 2006)